A Search Service for Abbreviation / Long Form

■ Search Result - Abbreviation : PD-L1

Search Conditions:
Search Keyword : PD-L1
Search Method : Exact match.
Research Area:

Results:  
Abbreviation: PD-L1
Appearance Frequency: 5901 time(s)
Long forms: 43

Display Settings:
[Entries Per Page]
 per page
Page Control
Page: of
Long Form No. Long Form Research Area Co-occurring Abbreviation PubMed/MEDLINE Info. (Year, Title)
programmed death-ligand 1
(5419 times)
Neoplasms
(2313 times)
PD-1 (1281 times)
NSCLC (872 times)
OS (660 times)
2004 Schistosoma mansoni worms induce anergy of T cells via selective up-regulation of programmed death ligand 1 on macrophages.
PD-ligand 1
(330 times)
Neoplasms
(117 times)
PD-1 (223 times)
NSCLC (36 times)
CTLA-4 (35 times)
2001 Laser capture microdissection-based expression profiling identifies PD1-ligand as a target of the nude locus gene product.
protein ligand 1
(72 times)
Neoplasms
(28 times)
NSCLC (17 times)
ICIs (14 times)
CTLA-4 (10 times)
2016 Near infrared photoimmunotherapy with avelumab, an anti-programmed death-ligand 1 (PD-L1) antibody.
anti-PD-ligand 1
(11 times)
Neoplasms
(5 times)
PD-1 (8 times)
CTLA-4 (4 times)
DCs (2 times)
2017 Biomarkers to predict prognosis and response to checkpoint inhibitors.
PD-1 and its ligand
(10 times)
Neoplasms
(4 times)
PD-1 (3 times)
OS (2 times)
Abs (1 time)
2007 Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection.
programmed death ligand 1 protein
(9 times)
Neoplasms
(4 times)
IHC (2 times)
TNBC (2 times)
ACC (1 time)
2015 Epitope characterization of an anti-PD-L1 antibody using orthogonal approaches.
programmed cell death 1
(5 times)
Neoplasms
(2 times)
HNSCC (2 times)
CTLA-4 (1 time)
eTregs (1 time)
2017 Pneumotoxicity associated with immune checkpoint inhibitor therapies.
programed death-1 receptor and its ligand
(4 times)
Neoplasms
(2 times)
CT (1 time)
CTLA-4 (1 time)
irAEs (1 time)
2014 Treatment paradigms for patients with metastatic non-small cell lung cancer, squamous lung cancer: first, second, and third-line.
programmed cell death ligand-1 protein
(4 times)
Pathology
(2 times)
HR (1 time)
HSP90alpha (1 time)
OS (1 time)
2016 PD-L1, PD-1, CD4, and CD8 expression in neoplastic and nonneoplastic thymus.
10  programmed cell death receptor-1
(3 times)
Biomedical Research
(1 time)
ALDH2 (1 time)
CRC (1 time)
DCs (1 time)
2016 Mesenchymal Stem Cells Upregulate the Expression of PD-L1 But Not VDR in Dendritic Cells.
11  programmed death-ligand 1 receptor
(2 times)
Neoplasms
(2 times)
OS (2 times)
AR (1 time)
BMI (1 time)
2019 Prognostic markers in salivary gland cancer and their impact on survival.
12  1-PD-1-ligand
(1 time)
Biology
(1 time)
APCs (1 time)
CTLA-4 (1 time)
PD (1 time)
2003 T cell costimulatory pathways: blockade for autoimmunity.
13  anti-anti-Programmed Death Ligand-1
(1 time)
Neoplasms
(1 time)
ICI (1 time)
mccRCC (1 time)
NSCLC (1 time)
2021 Tumor Microenvironment Features as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors (ICI) in Metastatic Clear Cell Renal Cell Carcinoma (mccRCC).
14  demonstratedprogrammed death ligand-1
(1 time)
GI (1 time)
IHC (1 time)
NCCN (1 time)
2020 Gastric Cardia Adenocarcinoma with Metastasis to the Scalp: A Case Report.
15  particular, we focused on IL4I1+CD274
(1 time)
Allergy and Immunology
(1 time)
IFN-gamma (1 time)
MNPs (1 time)
2021 Cross-tissue single-cell landscape of human monocytes and macrophages in health and disease.
16  PD-1 and its 2 B7 family ligands, B7-H1
(1 time)
Hematology
(1 time)
CTLs (1 time)
HA (1 time)
2007 Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells.
17  PD-1 engagement to its ligand
(1 time)
Medicine
(1 time)
CMV (1 time)
PD-1 (1 time)
2006 Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction.
18  PD-1 ligand expression
(1 time)
Immunotherapy
(1 time)
CTLA-4 (1 time)
PD-1 (1 time)
SITC (1 time)
2016 Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation.
19  PD-1 ligand-positive T cells
(1 time)
Allergy and Immunology
(1 time)
IFN (1 time)
IL (1 time)
MTB (1 time)
2016 Programmed death-1+ T cells inhibit effector T cells at the pathological site of miliary tuberculosis.
20  PD-1 on CD4+CD25+ Tregs, CD19+ cells and its ligand
(1 time)
Allergy and Immunology
(1 time)
BI (1 time)
2016 Increased IL-35 producing Tregs and CD19+IL-35+ cells are associated with disease progression in leprosy patients.
21  PD-1 on Tcells and its ligand
(1 time)
Biological Science Disciplines
(1 time)
APCs (1 time)
2018 Antigen-Presenting Cell-Intrinsic PD-1 Neutralizes PD-L1 in cis to Attenuate PD-1 Signaling in T Cells.
22  PD-1 on Tregs, B cell and its ligand
(1 time)
Allergy and Immunology
(1 time)
BI (1 time)
2016 Increased IL-35 producing Tregs and CD19+IL-35+ cells are associated with disease progression in leprosy patients.
23  PD-1 receptor ligand
(1 time)
Immune System Diseases
(1 time)
PD-1 (1 time)
2014 Autoimmunity as a double agent in tumor killing and cancer promotion.
24  PD-1, namely, B7-H1
(1 time)
Allergy and Immunology
(1 time)
DCs (1 time)
PD-1 (1 time)
2002 Expression of programmed death 1 ligands by murine T cells and APC.
25  PD-1, the ligand of which
(1 time)
Antineoplastic Agents
(1 time)
PD-1 (1 time)
2018 Improved outcomes with pembrolizumab treatment in two cases of double cancer including non-small-cell lung cancer.
26  PD-L1 and TGF-beta than patients with advanced invasive thymic carcinoma
(1 time)
OS (1 time)
PFS (1 time)
TETs (1 time)
2018 Impact of PD-L1, transforming growth factor-beta expression and tumor-infiltrating CD8+ T cells on clinical outcome of patients with advanced thymic epithelial tumors.
27  PD-L1 and, more recently, chromosomal 9p24.1/CD274
(1 time)
Pathology
(1 time)
FISH (1 time)
IHC (1 time)
PD-L2 (1 time)
2018 Immune checkpoint blockade as a potential therapeutic strategy for undifferentiated malignancies.
28  PD-L1 expression ( 1%) and 14 (18 %) had high
(1 time)
Pathology
(1 time)
ICP (1 time)
2021 Distribution and Expression of Programmed Death Ligand -1 (PD-L1) in Non-Small Cell Carcinomas of the Lung in a Tertiary Care Centre in South India.
29  PD-L1 IHC
(1 time)
Pathology
(1 time)
NSCLC (1 time)
2016 [Predictive PD-L1 immunohistochemistry for non-small cell lung cancer : Current state of the art and experiences of the first German harmonization study].
30  PD-L1 protein expression using two IHC assays, mRNA
(1 time)
Genetics, Medical
(1 time)
NSCLC (1 time)
2019 PD-L1 gene copy number and promoter polymorphisms regulate PD-L1 expression in tumor cells of non-small cell lung cancer patients.
31  PD-L1 selected patients
(1 time)
Neoplasms
(1 time)
ICIs (1 time)
ORR (1 time)
OS (1 time)
2021 Efficacy of immune-checkpoint inhibitors in PD-L1 selected or unselected patients vs. control group in patients with advanced or metastatic urothelial carcinoma.
32  PD-L1 TM
(1 time)
Neoplasms
(1 time)
OS (1 time)
PD-L1 ME (1 time)
PFS (1 time)
2020 Prognostic significance of EGFR, MUC1 and PD-L1 expressions in cases with triple negative breast cancer.
33  PD-L1-CD
(1 time)
Biology
(1 time)
--- 2021 PD-L1 degradation is regulated by electrostatic membrane association of its cytoplasmic domain.
34  PD-L1-lnc
(1 time)
Genetics
(1 time)
LUAD (1 time)
2021 PD-L1 lncRNA splice isoform promotes lung adenocarcinoma progression via enhancing c-Myc activity.
35  PD-L1High
(1 time)
Molecular Biology
(1 time)
ALDH (1 time)
PD-1 (1 time)
TNBCs (1 time)
2019 WNT signaling modulates PD-L1 expression in the stem cell compartment of triple-negative breast cancer.
36  plasma cells, are CD19-negative, and express B7-H1
(1 time)
Hematology
(1 time)
MM (1 time)
2009 A subpopulation of malignant CD34+CD138+B7-H1+ plasma cells is present in multiple myeloma patients.
37  production of T cells via interaction with its ligands, B7-H1
(1 time)
Allergy and Immunology
(1 time)
--- 2013 Negative role of inducible PD-1 on survival of activated dendritic cells.
38  programmed cell death ligand 1 antibody
(1 time)
Biomedical Engineering
(1 time)
Treg (1 time)
2019 Regulatory T Cells Tailored with pH-Responsive Liposomes Shape an Immuno-Antitumor Milieu against Tumors.
39  Programmed Cell Death-L1
(1 time)
Ophthalmology
(1 time)
ACC (1 time)
IHC (1 time)
MMR (1 time)
2021 Expression of Programmed Cell Death-L1 (PD-L1) Protein and Mismatch Repair Mutations in Orbital Tumours-a Pilot Study.
40  Programmed Death Cell Ligand 1
(1 time)
Vascular Diseases
(1 time)
OS (1 time)
TIMs (1 time)
2017 Programmed Death Cell Ligand 1 (PD-L1) Is Associated With Survival in Stage I Non-Small Cell Lung Cancer.
41  programmed death-ligand 1, B7-H1, CD274
(1 time)
Neoplasms
(1 time)
ICI (1 time)
TAT (1 time)
2021 Anti-Tumor Efficacy of PD-L1 Targeted Alpha-Particle Therapy in a Human Melanoma Xenograft Model.
42  programmed receptor-ligand 1
(1 time)
Pharmacology
(1 time)
CCA (1 time)
COX-2 (1 time)
IFN-gamma (1 time)
2021 Inhibition of T-cell-mediated immune response via the PD-1/ PD-L1 axis in cholangiocarcinoma cells.
43  protein death ligand 1
(1 time)
CTLA-4 (1 time)
ICI (1 time)
NLRs (1 time)
2021 Targeting Innate Immunity in Cancer Therapy.